Clinical Trial

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 6 locations 2026-05-09
Trial Details
NCT Number NCT07297979
Lead Sponsor Amgen
Conditions Ewing Sarcoma
Enrollment 50 participants
Start Date 2026-04-08
Primary Completion 2030-05-26 (estimated)
Study Completion 2030-05-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-16